Menopause Hormone Therapy, Explained Properly

Few treatments in modern medicine have swung between "miracle" and "menace" as violently as menopause hormone therapy. Millions of women stopped it almost overnight in 2002, many on the advice of a headline rather than a doctor. Twenty years of careful reanalysis have produced a much more balanced picture, but the fear arrived faster than the correction, and many women my patients' age are still carrying the 2002 version.

Here is the fuller story: what hormone therapy actually is, what the famous study really showed, and what the risks look like when you write them as real numbers instead of percentages.

What hormone therapy actually is#

Menopause happens when the ovaries stop producing estrogen. For most women the awkward years are the transition, when levels swing, and the first years after the final period, when the body adjusts to running without it. Hot flashes, night sweats, broken sleep, joint aches, mood changes, brain fog, vaginal dryness: most of these trace back to falling estrogen.

Hormone therapy, often called HRT or HT or MHT, replaces some of that estrogen. There are two basic forms, and the difference matters more than most people realize.

• Estrogen alone is used for women who have had a hysterectomy.
• Estrogen plus a progestogen is used for women who still have a uterus. Estrogen on its own stimulates the uterine lining and, unopposed over time, raises the risk of endometrial cancer. The progestogen exists to protect the lining. It is not optional.

Estrogen comes as tablets, skin patches, gels, and sprays. The route matters: estrogen through the skin bypasses the liver and does not appear to raise the risk of blood clots the way tablets do, which is one reason patches and gels are now often preferred. The progestogen may be a tablet, part of a combined patch, or a hormonal intrauterine device.

Separate from all of this is low-dose vaginal estrogen: creams, tablets, or rings placed locally to treat dryness, painful sex, and some urinary symptoms. Very little reaches the bloodstream, and the systemic risks discussed below do not apply in the same way.

What systemic hormone therapy does well is not in dispute. It is the most effective treatment known for hot flashes and night sweats, typically reducing their frequency by around 75 percent. It treats vaginal and urinary symptoms, often improves sleep and the mood symptoms that ride on top of broken sleep, and it prevents the rapid bone loss of early menopause, reducing fractures. No alternative matches it for symptom relief.

The WHI story: how good news became a 20-year scare#

Through the 1990s, hormone therapy was widely prescribed, partly on observational evidence suggesting it protected the heart. The Women's Health Initiative (WHI) was the huge randomized trial, more than 27,000 women, designed to test that properly.

In July 2002 the combined estrogen plus progestin arm was stopped early, and the announcement led news bulletins worldwide: increased breast cancer, heart disease, stroke, and blood clots. Prescriptions fell by more than half within two years. A generation of doctors trained in the aftermath simply stopped offering it, and a generation of women toughed out severe symptoms because they believed the alternative was cancer.

Three things got lost in the noise.

First, the numbers were reported as relative risks. A "26 percent increase in breast cancer" sounds terrifying. In absolute terms it was roughly 8 extra cases per 10,000 women per year. Both statements are true. Only one of them frightened millions of women off treatment.

Second, the trial population did not look like the women actually asking for help. The average participant was 63, more than a decade past menopause. Many were overweight; many had existing cardiovascular risk. The results were then applied to healthy 51-year-olds with hot flashes, who were barely represented.

Third, the two arms were merged in the public mind. The estrogen-only arm, in women with hysterectomy, showed no increase in breast cancer. Over longer follow-up it showed a reduction. Almost nobody heard that part.

How the picture was corrected#

The correction did not come from a rival study. It came largely from the WHI's own data, reanalyzed by age.

When investigators separated women who started therapy in their 50s from those who started in their 60s and 70s, the risk pattern split. Younger, recently menopausal women showed no clear increase in heart disease, and in some analyses a decrease, along with lower overall mortality. The excess cardiac risk was concentrated in women starting many years after menopause. Long-term follow-up published over the following two decades found no increase in overall death rates in either arm, at any age, after 18 years.

This produced the timing hypothesis: estrogen appears to behave differently depending on the state of the arteries when it arrives. Started early, when vessels are still healthy, it appears neutral or possibly favorable for the heart. Started late, on top of established plaque, it may destabilize things and raise early cardiac and stroke risk. The biology is plausible and the epidemiology fits, though "early start protects the heart" remains unproven, and no guideline recommends hormone therapy to prevent heart disease.

Out of all this came the current consensus, reflected in guidance from The Menopause Society and others: for healthy women with troublesome symptoms who start within 10 years of their final period and before age 60, the benefits of hormone therapy generally outweigh the risks. Outside that window, caution increases, and the conversation changes.

The risks in real numbers#

Percentages mislead; counts inform. These are approximate absolute figures per 10,000 women per year drawn from the WHI, for women using combined therapy, alongside everyday comparisons.

Put another way: over one year, roughly 9,990 of 10,000 women on combined therapy will not have a breast cancer attributable to it. The risk is real, it grows with duration of use beyond about five years, and it declines after stopping. It is also of the same order as common lifestyle exposures nobody holds a press conference about.

Who tends to benefit, and who needs more caution#

Benefit is greatest for women with moderate to severe hot flashes and night sweats, women within 10 years of menopause, and women with early menopause or premature ovarian insufficiency (before 45, and especially before 40). That last group is not really "choosing hormone therapy" in the usual sense; they are replacing hormones their bodies were expected to make, and most guidance supports treatment at least until the average age of menopause, around 51, to protect bones, heart, and brain.

Hormone therapy is also a reasonable option to discuss for preventing osteoporosis in younger menopausal women at high fracture risk who cannot use other bone treatments.

More caution, and sometimes a clear no, applies with: a history of breast cancer or other hormone-sensitive cancer, previous blood clots or stroke, established heart disease, active liver disease, unexplained vaginal bleeding, or starting more than 10 years past menopause. Caution is not always prohibition. A history of clots may steer the conversation toward transdermal estrogen rather than away from treatment entirely. These are exactly the cases where a doctor who knows menopause medicine earns their keep.

None of this is a decision to make from an article, including this one. Hormone therapy is a discussion to have with your own doctor, with your full history on the table.

Alternatives, with honest evidence#

For women who cannot or prefer not to use hormones, there are real options. Honesty requires saying that they help less, on average, than estrogen does.

• Certain antidepressant classes (SSRIs and SNRIs) reduce hot flash frequency modestly in trials, clearly better than placebo, clearly less than estrogen. One is specifically approved in the US for hot flashes. Worth discussing if hormones are off the table.
• A newer nonhormonal class, neurokinin receptor blockers, targets the brain's temperature-control circuit directly. Trial results for hot flashes are genuinely impressive for a nonhormonal drug. This class is new, so long-term data are still accumulating. Ask your doctor about it by class if you have severe flashes and cannot take estrogen.
• Gabapentinoids and clonidine have modest evidence, with sedation and side effects limiting their appeal.
• Cognitive behavioral therapy does not reduce the number of flashes much, but reliably reduces how much they bother you and improves sleep. Underrated.
• Exercise, weight management, alcohol reduction, and dressing in layers are all sensible, though trial evidence that they reduce flashes is weak. They earn their place on general health grounds.
• Black cohosh, red clover, soy isoflavones: trial results are inconsistent and mostly little better than placebo, which itself reduces flashes by around 25 to 30 percent. Quality control of supplements is poor.
• Compounded bioidentical hormones deserve their own sentence: marketed as natural and safe, they are unregulated, untested, and inconsistently dosed, and every major menopause society advises against them. Regulated body-identical options exist on prescription; ask for those instead.

What I actually see in clinic#

The conversation I have most often is with a woman in her early 50s who has not slept properly in a year, is soaking a nightdress most nights, and opens with "but I don't want to get cancer." She is usually astonished to see the WHI numbers written down as counts rather than percentages, and even more astonished to hear that the estrogen-only arm showed no increase at all.

What strikes me is how often the decision, once informed, goes both ways. Some women look at the numbers and choose treatment without hesitation. Others look at the same numbers and prefer to manage without, and with sleep measures, a fan, and sometimes a nonhormonal option, do well. Both are rational. My job, and your doctor's, is not to sell either path. It is to make sure the choice is made on 2026 evidence rather than a 2002 headline.

The saddest cases are the women who suffered severe symptoms for a decade because nobody reopened the question, and who now, 15 years past menopause, have mostly missed the window where starting is straightforward.

Questions worth asking your doctor#

Take this list in. A good clinician will welcome it.

• Given my age and time since my last period, am I inside the window where benefits usually outweigh risks?
• Do my personal and family history change my risk picture, and how?
• Estrogen through the skin or by tablet, and why, for me specifically?
• Which progestogen, and would a hormonal IUD do that job?
• If systemic therapy is not right for me, is vaginal estrogen still an option for dryness and urinary symptoms?
• What nonhormonal options fit my situation?
• How and when will we review the decision, and what would make us change course?

When to get help now#

Whether or not you use hormone therapy, some things should never wait for a routine review. Any vaginal bleeding after menopause needs assessment, always. A new breast lump, skin dimpling, or nipple discharge needs prompt review. Sudden one-sided leg swelling or pain, sudden breathlessness, or chest pain can signal a clot and needs emergency care. So does any sudden severe headache, facial droop, weakness, or trouble speaking.

The bottom line#

Hormone therapy is neither a fountain of youth nor a poison. It is the most effective treatment for menopausal symptoms, with small absolute risks that depend heavily on your age, your health, and when you start. For healthy symptomatic women within about 10 years of menopause, the balance is usually favorable; started much later, it may not be. The 2002 scare was a lesson in what relative risk does to public understanding, and the correction deserves to be as well known as the fright. Take the real numbers to your own doctor, and make the decision that fits your body and your priorities.